In Silico Modeling for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

Request Number REQ0334262
Due Date March 1, 2017
Author Seh-Rin Sung
Request for Proposal Details
RFP Title
In Silico Modeling for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
RFP Description

NineSigma, representing Daiichi Sankyo Co., Ltd. (, seeks a partner for the development of an in silico model which can reflect the behavior of various biomarkers that change with the inhibition of parathyroid hormone (PTH) in chronic kidney disease-mineral and bone disorder (CKD-MBD).


Increased blood levels of PTH, resulting from decreased activated vitamin D level or accumulation of phosphorus, have been found in patients with CKD. Subsequently, the following changes are known to occur.

1)Changes in bone metabolism associated with activation of PTH receptor signaling pathway

2)Changes in circulating bone metabolism markers

3)Changes in bone density/quality

4)Increased incidence of bone fracture


Daiichi Sankyo aims at creating a novel drug for CKD-MBD focusing on PTH signal regulation with efficient development process driven by markers that respond to PTH signals. The client has decided to seek a partner to develop an in silico model of CKD-MBD incorporating biomarkers that change in response to PTH signals, including bone metabolism markers, bone density, bone quality and fracture risk, and to identify markers (a group of markers) that can be used as a surrogate of PTH signal alteration. 



Key Success Criteria

Requirements for in silico model

The proposed model should meet the following requirements.

  • Use of Matlab/SimBiology as a platform.
  • Literature and clinical information needed for developing a model are organized and linked to the model explicitly.
    • Literature and clinical information, which form the basis of model development, are as follows but not limited to:
      • Clinical data on progression of CKD
      • Clinical data of existing drugs for secondary hyperparathyroidism.
      • Clinical data at parathyroidectomy
  • Model describes and quantitatively represents physiological effects of PTH in CKD-MBD.
  • Model can reproduce clinical data on existing drugs for secondary hyperparathyroidism (e.g. cinacalcet).
  • Model can identify surrogate markers (a group of markers) of PTH signal alteration consisting of clinically measurable markers.
  • Model can suggest the most appropriate target patient population of our novel drug for CKD-MBD.
  • Modeling workflow is established and can be described in a document.


In addition to the above, it is desirable that a proposer has experience with modeling in the field of CKD-MBD.


Proposed technology does not necessarily meet the above requirements at present. The client will accept the proposal if the evidences which show feasibility for meeting those requirements within 6 months are presented.


Preferred Collaboration types
Items to be submitted

Anticipated Project Phases or Project Plan

The proposing organization is required to submit proposals using the attached Response Template.


The client will review proposals and select suitable candidates for collaboration. Once candidates are selected, the client will execute confidential disclosure agreements (CDAs) in order to seek further information disclosure and discuss possible research approaches.

Once the best candidates have been determined, the client will execute licensing/joint/contract research agreements with partners.


Items to be Included in the Proposal

Responses will use the Proposal Template which is linked to the “attachments“ shown at the bottom of this page and include the following items:


  • Outline of in silico model (principle, bone-related markers which can be incorporated)
  • Examples of past experience
  • Current modeling stage
  • Future modeling plans
  • Desired collaboration framework with the client
  • Related intellectual properties
  • Organization overview and past achievements

Area of Interest
Request Priority